Åsa Bergström New COO at Nanologica AB (publ)
Åsa Bergström will take over as COO at Nanologica AB on May 1 after the current COO Anna-Karin Renström leaves the company on April 26. Åsa Bergström also joins Nanologica’s management team.
Åsa Bergström, born 1964, holds a Master of Science in Chemical Engineering and Biotechnology from KTH Royal Institute of Technology and an MBA Global Executive Management from Copenhagen Business School. Åsa joins Nanologica from pharmaceutical contract manufacturer Recipharm where she held the position of Director Global Sustainability. Åsa has prior held several roles at Recipharm as Site Manager Recipharm Development, Director Corporate Projects, as well as Environmental Manager, and has worked with system management, aquisitions, and project management for factory constructions at Recipharm.
“We are incredibly happy to welcome Åsa to our team as the new COO after Anna-Karin leaves her position. Åsa’s solid knowledge and experience, combined with her great drive, makes her very well suited for the role as our COO. I would also like to take this opportunity to thank Anna-Karin for her loyal and diligent work for Nanologica and we wish her all the best in the future – she will be missed by the entire team”, CEO Andreas Bhagwani comments.
Åsa will take up her position on May 1 and will join Nanologica’s management team.
For further information, please contact
Johanna Johansson
Director IR, Communications and Marketing
johanna.johansson@nanologica.com
+46 72 211 21 90
About Nanologica AB (publ)
Nanologica is a Swedish life science tools company that provides consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market. For further information, please visit www.nanologica.com.
Attachments
Åsa Bergström New COO at Nanologica AB (publ)